Efficacy and Safety of Risankizumab in Paediatric Patients With Psoriasis in the OptIMMize-1 Phase III Study. (PubMed, Br J Dermatol) - Sep 26, 2026 - P3 | "Risankizumab was well tolerated in paediatric patients, resulting in marked improvements in skin clearance, itching, and quality of life after 16 weeks of treatment. Efficacy was maintained or improved at week 52, supporting risankizumab use for moderate-to-severe psoriasis in this population."
Journal • P3 data • Dermatology • Immunology • Pediatrics • Psoriasis
|
|
Adam Reich; Akimichi Morita; Amy S Paller; Asunción Vicente; Dolly Sharma; Doug Ashley; Irene Lara-Corrales; Kristina Unnebrink; Michael Bukhalo; Nina Magnolo; Ronilda D'Cunha; Rosie D Lyles; Toni Anschutz; Tshepiso Madihlaba; Wine Lee Lara
|